Kymera Therapeutics Inc [KYMR] stock is trading at $51.01, up 3.83%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The KYMR shares have gain 7.89% over the last week, with a monthly amount glided 19.77%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Kymera Therapeutics Inc [NASDAQ: KYMR] stock has seen the most recent analyst activity on September 18, 2025, when H.C. Wainwright reiterated its Buy rating and also boosted its price target to $70 from $60. Previously, Barclays started tracking the stock with Overweight rating on September 17, 2025, and set its price target to $60. On September 16, 2025, RBC Capital Mkts initiated with a Outperform rating and assigned a price target of $70 on the stock. Morgan Stanley upgraded its rating to Overweight for this stock on June 03, 2025, but kept the price target unchanged to $79. In a note dated June 03, 2025, B. Riley Securities upgraded a Buy rating on this stock but restated the target price of $60.
Kymera Therapeutics Inc [KYMR] stock has fluctuated between $19.44 and $53.27 over the past year. Currently, Wall Street analysts expect the stock to reach $62.29 within the next 12 months. Kymera Therapeutics Inc [NASDAQ: KYMR] shares were valued at $51.01 at the most recent close of the market. An investor can expect a potential return of 22.11% based on the average KYMR price forecast.
Analyzing the KYMR fundamentals
Kymera Therapeutics Inc [NASDAQ:KYMR] reported sales of 44.71M for the trailing twelve months, which represents a drop of -55.26%. Gross Profit Margin for this corporation currently stands at 0.95% with Operating Profit Margin at -6.98%, Pretax Profit Margin comes in at -6.16%, and Net Profit Margin reading is -6.16%. To continue investigating profitability, this company’s Return on Assets is posted at -0.24, Equity is -0.32 and Total Capital is -0.3. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.09.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 48.93 points at the first support level, and at 46.85 for the second support level. However, for the 1st resistance point, the stock is sitting at 52.06, and for the 2nd resistance point, it is at 53.11.
Ratios To Look Out For
For context, Kymera Therapeutics Inc’s Current Ratio is 8.32. Further, the Quick Ratio stands at 8.32, while the Cash Ratio is 3.84. Considering the valuation of this stock, the price to sales ratio is 81.57, the price to book ratio is 3.70.
Transactions by insiders
Recent insider trading involved Jacobs Bruce N., Chief Financial Officer, that happened on Sep 17 ’25 when 79220.0 shares were sold. Officer, BRUCE N. JACOBS completed a deal on Sep 17 ’25 to buy 79220.0 shares. Meanwhile, Chief Executive Officer Mainolfi Nello sold 30000.0 shares on Sep 16 ’25.
